Paris, France based Sofinnova Partners (www.sofinnova.fr) raised a new €300 million healthcare fund, above the initial fund target of €250 million. Sofinnova Capital VIII will invest in the healthcare industry and more specifically in the biopharmaceutical and medical device sectors. Sofinnova Partners will seek to invest as a founding and lead investor in start-ups and corporate spin-offs and focus on therapeutic “paradigm shifting” technologies and products alongside visionary entrepreneurs. Sofinnova Capital VIII will invest about two thirds of its funds in European companies and one third outside of Europe, primarily in North America. Two Wharton MBA alumni, Managing Partner, Antoine Papiernik (WG’92) and Senior Associate Katie Ellias (WHCM’06) are among the 12 experienced investment professionals in the new fund.